Unique fermented turmeric extract promotes weight loss and glucose metabolism by promoting GLP-1 production in overweight individuals

A prospective, randomized, double-blind, two-arm, parallel, clinical study to evaluate the efficacy of fermented turmeric extract supplementation on weight loss and glucose metabolism in healthy overweight participants

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN18361592

Enrollment

Registered

2025-11-13

Start date

2024-10-01

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Improvement of glucose metabolism in overweight participants Nutritional, Metabolic, Endocrine

Interventions

This study investigates 8 weeks of daily supplementation with Fermented Turmeric Extract (300 mg/day, one capsule) or a commercially available Turmeric Extract (300 mg/day, one capsule) taken orally a

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. BMI between 28 and 35 kg/m² 2. Commitment to maintaining their usual dietary habits and physical activity levels throughout the study period.

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Lactation 3. History of serious medical conditions such as cancer 4. Known allergies to turmeric or any component of the test product 5. Use of medications or dietary supplements that could impact body weight or metabolic function

Design outcomes

Primary

Measure	Time frame
1. Weight measured using a calibrated digital weighing scale at day 0 and day 56 2. Fat mass, lean mass, BMI measured using a bioelectrical impedance analysis at day 0 and day 56 3. Waist circumference, hip circumference, thigh circumference measured at day 0 and day 56	—

Secondary

Measure	Time frame
1. GLP-1 levels measured using an enzyme-linked immunosorbent assay at day 0 and day 56 2. PYY levels measured using an enzyme-linked immunosorbent assay at day 0 and day 56 3. Ghrelin leptin and adiponectin levels measured using an enzyme-linked immunosorbent assay at day 0 and day 56 4. Blood glucose measured using a hexokinase enzymatic method at day 0 and day 56 5. Insulin level measured using a chemiluminescent immunoassay at day 0 and day 56 6. Fecal microbiome composition measured using quantitative PCR at day 0 and day 56	—

Measure

Time frame

1. GLP-1 levels measured using an enzyme-linked immunosorbent assay at day 0 and day 56 2. PYY levels measured using an enzyme-linked immunosorbent assay at day 0 and day 56 3. Ghrelin leptin and adiponectin levels measured using an enzyme-linked immunosorbent assay at day 0 and day 56 4. Blood glucose measured using a hexokinase enzymatic method at day 0 and day 56 5. Insulin level measured using a chemiluminescent immunoassay at day 0 and day 56 6. Fecal microbiome composition measured using quantitative PCR at day 0 and day 56

—

Countries

Japan

Contacts

Public ContactYuki Ikeda

development@innovationlabo.com+81 (0)335525335

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026